VRDN
Viridian Therapeutics, Inc.\DE
NASDAQ · Healthcare · Biotechnology · US
$22.00
+0.32%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$21.94
From 52W high−34.87%
Volume5.35M
Market cap$2.49B
P/E (TTM)—
P/S (TTM)35.0x
Div yield—
Key dataSep 18, 2026
Open
$21.94
From 52W high
−34.87%
Volume
5.35M
Market cap
$2.49B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.0x
P/E (TTM)
—
RSI (14)
46.1
MomentumView details →
1D Return
+0.32%
YTD Return
−29.62%
SummaryUpdated Jun 1, 2026
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a clinical-stage biotechnology company founded in 2006 and headquartered in Waltham, Massachusetts. Originally established as Miragen Therapeutics, the company underwent a strategic transformation and rebranded to Viridian Therapeutics in January 2021. The company has evolved from its initial focus on microRNA-based therapeutics to become a specialized developer of antibody treatments targeting serious autoimmune and rare diseases, with particular emphasis on thyroid eye disease.
Similar companies
Latest newsMore news →
Viridian Therapeutics reported its Q2 2026 financial results, with total revenues of $284,000 and a net loss of $127.1 million.46d agoViridian Therapeutics received early FDA approval for Lumvoa, a treatment for thyroid eye disease.82d agoThe U.S. FDA approved Lumvoa (veligrotug-vvze) developed by Viridian Therapeutics for the treatment of thyroid eye disease.86d ago